Reminder: Palivizumab program paused and RSV surveillance continues

The purpose of the palivizumab program is to reduce the risk of Respiratory Syncytial Virus (RSV) associated hospitalization in high-risk infants at risk for complications from RSV. Although the Nova Scotia palivizumab program usually runs from December to April, the program was paused on February 8, 2021 as no circulation of RSV had been detected in the province. See: Palivizumab Program Pause letter Feb 2021.pdf (nshealth.ca) The IWK and the Nova Scotia Department of Health and Wellness will continue to monitor the incidence of RSV across the province past the usual season and assess the need for prophylaxis. Please continue to submit applications for the program using the Nova Scotia RSV Prophylaxis Request Form 2020-2021 and fax completed forms to AbbVie Corporation at 1-888-703-6967. Eligibility criteria have not changed and are available at: https://www.iwk.nshealth.ca/palivizumab/provincial-guidelines/indications-for-use